Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI TKI) can render locally advanced, initially unresectable-or high-morbidity-thyroid cancers operable. The primary endpoint is conversion-to-surgery; key secondaries are R0/1 margin rate and 12-month event-free survival, with propensity-score weighting correcting cohort imbalances. Findings aim to define a precision-guided neoadjuvant standard for down-staging advanced thyroid tumors.
Phase:
PHASE4
Details
Lead Sponsor:
Fujian Medical University
Treatments:
anlotinib cabozantinib Conversion to Open Surgery dabrafenib larotrectinib lenvatinib pembrolizumab pralsetinib selpercatinib sintilimab trametinib